Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

Abstract

Objectives:To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods:Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results:After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP > 166 pg/mL) and normalized MCP-1 (MCP-1/TV >0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion:MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.

Perinatal mesenchymal stromal cells of the human decidua restore continence in rats with stress urinary incontinence induced by simulated birth trauma and regulate senescence of fibroblasts from women with stress urinary incontinence

“…Other authors have published in vivo data reporting the relevance of these chemokines in incontinence. MCP-3 has been found significantly over-expressed in urethral and vaginal tissues immediately following VD ( Woo et al, 2007 ), and MCP-1 has been determined to be a predictive biomarker of urinary incontinence in males undergoing prostatectomy ( Liss et al, 2016 ). In contrast, SDF-1 was significantly underexpressed in urethral and vaginal tissues after VD ( Woo et al, 2007 ), but it has been successfully evaluated as an experimental therapy for SUI in rats after VD based on its role in neovascularization and chemotaxis of stem cells ( Khalifa et al, 2020 ).…”